Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SHBG | P04278 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506530 | 1.00 | MEN1 (0.54) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL25243117 | 0.83 | — | — | |
| SCHEMBL25288911 | 0.83 | GRM2 (0.44) | GRM2 | |
| SCHEMBL12231322 | 0.81 | GRM2 (0.38) | GRM2 | |
| SCHEMBL480863 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL29639744 | 0.79 | MEN1 (0.58) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL26384131 | 0.78 | SHBG (0.58) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL6102044 | 0.77 | MEN1 (0.38) | MEN1KMT2AMAPTALDH1A1HTT | |
| SCHEMBL4388031 | 0.76 | MEN1 (0.55) | MEN1KMT2AMAPTSHBGHSD17B10 | |
| SCHEMBL29639745 | 0.76 | MEN1 (0.55) | MEN1KMT2AMAPTSHBGHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| EP-4452918-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-3129345-B1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2023-03-15 | — | — | EP | disclosed |
| US-10377695-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-08-13 | — | — | US | disclosed |
| US-10099993-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180194710-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-12 | — | — | US | disclosed |
| US-20170036987-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-09 | — | — | US | disclosed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170036987-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | GRM3, GRM2, GRM1 | MEN1 3296/4885KMT2A 944/4885MAPT 1240/4885 |
| US-10377695-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | GRM3, GRM2, GRM1 | MEN1 3296/4885KMT2A 944/4885MAPT 1240/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | MEN1 3296/4885KMT2A 944/4885MAPT 1240/4885 |
| US-10099993-B2 | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof | GRM3, GRM2, GRM1 | MEN1 3296/4885KMT2A 944/4885MAPT 1240/4885 |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | MEN1 4407/4885KMT2A 2204/4885MAPT 2102/4885 |
| US-20180194710-A1 | Metabotropic Glutamate Receptor Positive Allosteric Modulators (PAMS) and Uses Thereof | GRM3, GRM2, GRM1 | MEN1 3296/4885KMT2A 944/4885MAPT 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.